10 Best Small-Cap Stocks Ready To Explode

7. Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Analyst Upside Potential: 101.09%

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biopharmaceutical company that specializes in developing new medicines for serious and rare diseases, particularly focusing on thyroid eye disease (TED). This condition is an autoimmune disorder where the immune system attacks the tissues around the eyes, leading to symptoms like swelling, redness, and vision problems.

The company has made significant progress in its clinical trials and financial positioning as of the third quarter of 2024. It reported successful topline results for Veligrotug for TED from the THRIVE trial, a phase 3 clinical study evaluating Veligrotug, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody. Viridian Therapeutics, Inc. (NASDAQ:VRDN) is also on track to release topline data from THRIVE-2, which focuses on chronic TED patients, in December 2024. This trial has already exceeded its enrollment target with 188 patients.

With respect to VRDN-003, which is another next-generation, subcutaneous anti-insulin-like growth factor-1 receptor (IGF-1R) antibody developed by Viridian Therapeutics, Inc. (NASDAQ:VRDN). The company launched two pivotal phase 3 trials, REVEAL-1 and REVEAL-2, to assess VRDN-003. Topline data from these trials is expected in the first half of 2026.

Moreover, in terms of cash position, the company reported cash and equivalents totaling $753.2 million as of September 30, 2024. The cash position was significantly bolstered by a public offering that raised $243.2 million in September 2024. Management believes that the funding is projected to sustain operations into the second half of 2027. It is one of the best small-cap stocks ready to explode as analysts’ 12-month median price target is pointing towards a 101.09% increase from the current levels.